Synjardy FDA Approval History
FDA Approved: Yes (First approved August 26, 2015)
Brand name: Synjardy
Generic name: empagliflozin and metformin
Dosage form: Tablets
Company: Eli Lilly and Company and Boehringer Ingelheim
Treatment for: Diabetes, Type 2
Synjardy (empagliflozin and metformin hydrochloride) is a sodium glucose co-transporter-2 (SGLT2) inhibitor and biguanide combination for the treatment of adults with type 2 diabetes.
Development timeline for Synjardy
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.